Stockscreener 앱 받기
1.35
2.88%
-0.04
시간 외 거래:
1.36
0.01
+0.74%
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat
MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday - MarketBeat
MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38 - MSN
BREAKING: TRUMP JUST BOUGHT THIS STOCK! (01ajqP9sss) - fathomjournal.org
MAIA Biotechnology (MAIA) posts narrower Q4 2025 loss than analyst estimates, lifting shares 4.44 percent today.Joint Venture - Newser
MAIA Biotechnology | 8-K: Current report - Moomoo
MAIA Biotechnology opens first U.S. site for lung cancer trial By Investing.com - Investing.com Australia
MAIA Should I Buy - Intellectia AI
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update - MarketBeat
MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com
MAIA Expands THIO-101 Lung Cancer Trial in U.S. - TipRanks
MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M - TradingView
MAIA Biotechnology Activates First U.S. Site for THIO-101 Phase 2 Trial, Reporting Promising Efficacy in Advanced NSCLC Treatment - Quiver Quantitative
Form 8-KCurrent report - ADVFN
MAIA Biotechnology Activates First U.S. Site for Ongoing - GlobeNewswire
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan
EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn
Is MAIA Biotechnology (MAIA) Stock Slowing Down | Price at $1.25, Up 4.58%Profit Surge - Newser
Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart
Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times
MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan
MAIA Biotechnology Expects Recent $33 Million Capital Raise - GlobeNewswire
MAIA Biotechnology (NYSE American: MAIA) plans 2026 virtual shareholder meeting, pay vote - Stock Titan
MAIA Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Is MAIA Biotechnology (MAIA) Stock Good for Long Term | Price at $1.29, Down 3.01%Sector Leader - Newser
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - TipRanks
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - TipRanks
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView — Track All Markets
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2% - MarketBeat
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026 - The Globe and Mail
MAIA Biotechnology presents THIO-101 poster showing sustained responses in relapsed NSCLC - TradingView
MAIA Biotechnology (NYSE American: MAIA) presents ELCC 2026 trial poster - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - finance.yahoo.com
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MAIA Biotechnology, Inc. 2025 Annual 10-K SEC Filing Overview: Private Placements, Warrants, and Equity Transactions - Minichart
1.77%
0.25%
자본화:
|
볼륨(24시간):